Preferred Label : Tomivosertib;
NCIt synonyms : Spiro(cyclohexane-1,3'(2'H)-imidazo(1,5-a)pyridine)-1',5'-dione, 6'-((6-Amino-4-pyrimidinyl)amino)-8'-methyl-;
NCIt definition : An orally bioavailable inhibitor of mitogen-activated protein kinase (MAPK)-interacting
serine/threonine-protein kinase 1 (MNK1) and 2 (MNK2), with potential antineoplastic
activity. Upon oral administration, tomivosertib binds to and inhibits the activity
of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation
of certain regulatory proteins, including eukaryotic translation initiation factor
4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor
cell proliferation, angiogenesis, survival and immune signaling. This inhibits tumor
cell proliferation in MNK1/2-overexpressing tumor cells. MNK1/2 are overexpressed
in a variety of tumor cell types and promote phosphorylation of eIF4E; eIF4E is overexpressed
in many tumor cell types and contributes to tumor development, maintenance and resistance.;
UNII : U2H19X4WBV;
InChIKey : HKTBYUWLRDZAJK-UHFFFAOYSA-N;
CAS number : 1849590-01-7;
Molecule name : EFT-508;
NCI Metathesaurus CUI : CL503903;
Origin ID : C125062;
UMLS CUI : C5139867;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
